Completed PHASE2 INTERVENTIONAL NCT00455546

PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA)

PLASMA Trial: Phospholipase Levels And Serological Markers of Atherosclerosis: A Dose-Response Clinical Pharmacology Study of A-002 In Subjects With Stable Coronary Artery Disease

Sponsor: Anthera Pharmaceuticals

Conditions Coronary Artery Disease (CAD)

Interventions A-002

Updated 6 times since 2017 Last updated: Feb 1, 2010 Started: Apr 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00455546, this PHASE2 trial focuses on Coronary Artery Disease (CAD) and remains completed. Sponsored by Anthera Pharmaceuticals, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anthera Pharmaceuticals

Data source: Anthera Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Ann Arbor, United States , Auburn, United States , Augusta, United States , Austin, United States , Binghamton, United States , Camp Hill, United States , Dallas, United States , Detroit, United States , Dnepropetrovs'k, Ukraine and 20 more locations